Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes

Kidney International

Volumn 77, Issue 11, 2010, Pages 1000-1009

  Deb, Dilip K ^a   Sun, Tao ^a   Wong, Kari E ^a   Zhang, Zhongyi ^a   Ning, Gang ^b   Zhang, Yan ^a   Kong, Juan ^a   Shi, Helen ^c   Chang, Anthony ^a   Li, Yan Chun ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c HINES VA HOSPITAL   (United States)

Author keywords

albuminuria; compensatory renin increase; diabetic nephropathy; glomerulosclerosis; renin angiotensin system; vitamin D analogs

Indexed keywords

ALPHA ACTININ 4; ANGIOTENSIN I; ANGIOTENSIN II; CD2 ASSOCIATED PROTEIN; COLLAGEN TYPE 4; FIBRONECTIN; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEPHRIN; PARICALCITOL; PODOCIN; RENIN; TRANSFORMING GROWTH FACTOR BETA; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; AUTACOID; BIOLOGICAL MARKER; CREATININE; ERGOCALCIFEROL; LEPTIN RECEPTOR; LEPTIN RECEPTOR, MOUSE; MESSENGER RNA; SCLEROPROTEIN; VITAMIN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CELL COUNT; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; GLOMERULAR FILTRATION BARRIER; GLOMERULOSCLEROSIS; MALE; MESANGIUM; MONOTHERAPY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; ANIMAL; BLOOD; C57BL MOUSE; DISEASE COURSE; DISEASE MODEL; DRUG COMBINATION; GENE EXPRESSION REGULATION; GENETICS; GLOMERULUS; METABOLISM; PATHOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TIME; UREA NITROGEN BLOOD LEVEL; URINE;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIOLOGICAL MARKERS; BLOOD UREA NITROGEN; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ERGOCALCIFEROLS; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION; INFLAMMATION MEDIATORS; KIDNEY GLOMERULUS; LOSARTAN; MALE; MICE; MICE, INBRED C57BL; RECEPTORS, LEPTIN; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; TIME FACTORS; VITAMINS;

EID: 77955875400     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.22     Document Type: Article

References (38)

1. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265: F477-F486. (Pubitemid 23325866)
2. Zimpelmann J, Kumar D, Levine DZ et al. Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney Int 2000; 58: 2320-2330.
3. Singh R, Singh AK, Alavi N et al. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 2003; 14: 873-880. (Pubitemid 36359269)
4. Vidotti DB, Casarini DE, Cristovam PC et al. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol 2004; 286: F1039-F1045. (Pubitemid 38656357)
5. Yoo TH, Li JJ, Kim JJ et al. Activation of the renin-angiotensin system within podocytes in diabetes. Kidney Int 2007; 71: 1019-1027.
6. Chan JC, Ko GT, Leung DH et al. Long-term effects of angiotensinconverting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57: 590-600. (Pubitemid 30430651)
7. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
8. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
9. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
10. Andersen S, Tarnow L, Rossing P et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000; 57: 601-606. (Pubitemid 30430652)
11. Parving HH, Persson F, Lewis JB et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446. (Pubitemid 351793017)
12. Muller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006; 1: 221-228.
13. Nguyen G, Delarue F, Burckle C et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427. (Pubitemid 34596167)
14. Veniant M, Menard J, Bruneval P et al. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest 1996; 98: 1966-1970. (Pubitemid 26376283)
15. Zhang Z, Zhang Y, Ning G et al. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 2008; 105: 15896-15901.
16. Li YC, Kong J, Wei M et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-238. (Pubitemid 34787360)
17. Deb DK, Chen Y, Zhang Z et al. 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway. Am J Physiol Renal Physiol 2009; 296: F1212-F1218.
18. Yuan W, Pan W, Kong J et al. 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 2007; 282: 29821-29830. (Pubitemid 350035242)
19. Qiao G, Kong J, Uskokovic M et al. Analogs of 1alpha,25-dihydroxyvitamin D3 as novel inhibitors of renin biosynthesis. J Steroid Biochem Mol Biol 2005; 96: 59-66. (Pubitemid 41080519)
20. Fryer RM, Rakestraw PA, Nakane M et al. Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron Physiol 2007; 106: 76-81.
21. Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 2003; 284: F1138-F1144. (Pubitemid 36578440)
22. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634. (Pubitemid 40770751)
23. Kawachi H, Miyauchi N, Suzuki K et al. Role of podocyte slit diaphragm as a filtration barrier. Nephrology (Carlton) 2006; 11: 274-281. (Pubitemid 44086870)
24. Wang Y, Zhou J, Minto AW et al. Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy. Kidney Int 2006; 70: 882-891. (Pubitemid 44285965)
25. Matsunuma A, Horiuchi N. Leptin attenuates gene expression for renal 25-hydroxyvitamin D3-1alpha-hydroxylase in mice via the long form of the leptin receptor. Arch Biochem Biophys 2007; 463: 118-127. (Pubitemid 46879706)
26. Zhang Y, Deb DK, Kong J et al. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol 2009; 297: F791-F801.
27. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69: 2131-2147. (Pubitemid 43882099)
28. Perkins BA, Ficociello LH, Ostrander BE et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007; 18: 1353-1361. (Pubitemid 46536923)
29. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulindependent patients. N Engl J Med 1984; 311: 89-93. (Pubitemid 14084080)
30. Viberti GC, Hill RD, Jarrett RJ et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; 1: 1430-1432. (Pubitemid 12123979)
31. Agarwal R, Acharya M, Tian J et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828. (Pubitemid 43251029)
32. Alborzi P, Patel NA, Peterson C et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249-255.
33. Guijarro C, Egido J. Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney Int 2001; 59: 415-424. (Pubitemid 32157906)
34. Carey RM, Siragy HM. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol Metab 2003; 14: 274-281. (Pubitemid 36992197)
35. Li YC. Renoprotective effects of vitamin D analogs. Kidney Int 2009 in press.
36. Wong KE, Szeto FL, Zhang W et al. Involvement of the vitamin D receptor in energy metabolism: regulation of uncoupling proteins. Am J Physiol Endocrinol Metab 2009; 296: E820-E828.
37. Zhang Z, Sun L, Wang Y et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008; 73: 163-171.
38. Taneda S, Pippin JW, Sage EH et al. Amelioration of diabetic nephropathy in SPARC-null mice. J Am Soc Nephrol 2003; 14: 968-980. (Pubitemid 36359278)